Medexus Pharmaceuticals Inc. has seen a slight decline in its stock this week, amidst no major news updates.
Medexus Pharmaceuticals Inc. (MDP.TO) has experienced a modest drop in its stock price recently, closing at C$5.04, down 0.79% for the day and 1.75% for the week. Despite these fluctuations, the stock has shown a strong performance year-to-date, up 63.11%. As the company continues to navigate the healthcare landscape, let's explore the current state of Medexus Pharmaceuticals and its market position.
Investor takeaway: Investors should consider Medexus Pharmaceuticals' recent performance metrics and technical indicators, especially given the lack of recent news. With a solid year-to-date performance and a bullish analyst outlook, the company remains on the radar for those interested in the healthcare sector.
Advertisement
Medexus Pharmaceuticals Inc
MDP.TO
MDP.TO
Medexus Pharmaceuticals Inc
WealthAwesomeMarket cap
$162.47M
52W high
$5.50
52W low
$2.51
1W change
+0.00%
Beta
1.84
Analyst Price Targets
Based on analyst covering MDP
Wall Street analysts forecast MDP stock price to rise 40.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$7.25
+40.8% Upside
Current Price
C$5.15
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDP's historical volatility
30-Day Vol
30.5%
Annualized
90-Day Vol
40.0%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$6.16
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$5.47 | C$4.92 โ C$6.07 |
| 60 trading days | C$5.80 | C$5.00 โ C$6.73 |
| 90 trading days | C$6.16 | C$5.13 โ C$7.39 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Medexus Pharmaceuticals Inc. Closes at C$5.04 with Year-to-Date Gains of 63.11%
The stock has maintained a strong upward trajectory this year, but recent price movements suggest a potential consolidation phase.
Bull case
The bullish case for Medexus is rooted in its impressive year-to-date performance, driven by innovative products and recent licensing agreements. Notably, the UM171 Cell Therapy in Canada could enhance its oncology portfolio and expand its market reach.
Bear case
On the flip side, the bearish perspective points to the company's negative profit margins and limited media coverage, raising concerns about its long-term growth and sustainability in a competitive healthcare environment.
Recent Price Action
Medexus Pharmaceuticals Inc. (MDP.TO) closed at C$5.04, reflecting a 0.79% decrease for the day and a 1.75% decline over the past week. However, the stock has shown impressive growth of 20.00% over the last month and a significant year-to-date increase of 63.11%. This consistent upward trend indicates strong performance despite recent fluctuations.
Catalysts and News
Advertisement
Currently, there are no major news updates or significant announcements impacting Medexus Pharmaceuticals. However, the company has previously reported strong fiscal year results and has been active in expanding its product offerings, particularly with GRAFAPEX (treosulfan) for Injection and the recent licensing deal for UM171 Cell Therapy in Canada. These developments may contribute to investor interest moving forward.
Technical Picture
Looking at the technical indicators, Medexus Pharmaceuticals is currently trading above its 50-day moving average of C$4.29, which represents a 17.4% increase from the current price. The 200-day moving average stands at C$3.34, showing a 50.9% gain compared to the last closing price. The stock has a 52-week range of C$2.47 to C$5.25, indicating it is currently at 92% of its range. With a beta of 1.81, the stock is more volatile than the market, which may appeal to risk-tolerant investors.
Insider Activity
No recent insider activity has been reported for Medexus Pharmaceuticals, which typically indicates stability in management's commitment to the company's direction.
Price Action Summary
Medexus Pharmaceuticals Inc. closed at C$5.04, reflecting a daily drop of 0.79%. Despite the recent declines, the company's year-to-date performance remains strong, making it a notable player in the healthcare sector for Canadian investors.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
